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Abstract
Background: The transfer of cryopreserved embryos can be timed with ovulation in a 
natural cycle or after artificially preparing the endometrium with exogenous hormones. 
Progesterone is essential for the secretory transformation of the endometrium that per-
mits implantation as well as maintenance of early pregnancy. The purpose of this study 
is to assess the effect of luteal phase supplementation on pregnancy rates in natural 
frozen-thawed cycles.
Materials and Methods: The study was designed as a prospective randomized clinical 
trial of 102 women who underwent embryo transfers in natural cycles. The women in the 
interventional group (n=51) received intra muscular (IM) progesterone 50 mg twice a day 
starting from 36 hours after hCG administration. The control group (n=51) did not receive 
any progesterone support. 
Results: There were no significant differences in demographic characteristics between 
the groups and no statistically significant differences were observed between study and 
control groups in clinical pregnancy rate (33.3% vs. 27.5%, p=0.66). There were no dif-
ferences in implantation rate or spontaneous abortion rate.
Conclusion: Our results suggest that luteal phase support does not affect clinical preg-
nancy rates in natural frozen-thawed embryo transfer cycles (Registration Number: 
IRCT201108044339N6). 
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Introduction
Cryopreserved-thawed embryo transfer began 
in 1983 and became a popular, vital component of 
assisted reproduction technology (1). The transfer 
of a frozen embryo enhances the cumulative preg-
nancy rate, decreases cost, Is easy to perform 
and can be fulfilled successfully in a relatively 
shorter time span in comparison with repeated 
fresh cycles (2-5). Furthermore, endometrial 
receptivity can be compromised by controlled 
ovarian hyperstimulation (COH) protocols (6) 
and secretory endometrial transformation  (7). 
Endometrial development in frozen-thawed cy-
cles can be controlled more than during COH 
cycles (8).
Various protocols (gonadotropin/GnRH ago-
nists, clomiphene citrate, or exogenous estrogen 
and progesterone) have been discussed in lit-
erature reviews with regards to the endometrium 
preparation for frozen-thawed embryo transfer (3, 
9). The most prevalent protocol for frozen-thawed 
embryo transfer is the natural cycle or endometrial 
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preparation with exogenous estrogen and proges-
terone, with or without the addition of a GnRH 
agonist (10-12).
Because the natural cycle protocol does not re-
quire exogenous hormones‚ it is favored by many 
patients (13). It has been observed that temporal 
characteristics of the endometrium such as the 
formation of pinopodes (markers of endometrial 
receptivity) are out-of-phase according to meas-
urements in normal females who have been placed 
on exogenous steroids (14). Thus, the transfer of 
frozen-thawed embryos in natural cycles is a fa-
vored option for women with normal ovulatory 
menstrual cycles (15).
There is an idea that the endogenous pro-
duction of progesterone is enough to support 
implantation in a natural cycle. However, an 
inadequate progesterone level at the time of 
implantation or during early pregnancy may 
happen naturally due to luteal phase deficiency 
(LPD), which can result in infertility or abor-
tion (16).
The reported frequency of LPD ranges from 
3.7% to 20% among infertile patients (17, 18). 
The frequency has been demonstrated to be ap-
proximately 8.1% in natural cycles in normo-
ovulatory patients with primary or secondary 
infertility (19). Thus, women who undergo fro-
zen-thawed embryo transfers may have sub op-
timal endometrium during their natural cycles. 
There is limited information about the effect 
of luteal phase supplementation on pregnancy 
rate in natural frozen-thawed embryo transfer 
cycles. Therefore, we have designed a prospec-
tive randomized study to verify if pregnancy 
rates could be enhanced with progesterone sup-
plementation during the luteal phase and early 
pregnancy following a frozen-thawed embryo 
transfer in a natural cycle.
Materials and Methods
Study design
The study was designed as a prospective ran-
domized clinical trial. A total of 102 women 
each underwent an embryo transfer in a natural 
cycle in Yazd Research and Clinical Center for 
Infertility affiliated by Shahid Sadoughi Uni-
versity of Medical Sciences, from March 2011 
to March 2012. This study was approved by the 
Ethics Committee of Yazd Research and Clini-
cal Center for Infertility. Prior to starting the 
study‚ an informed consent was signed by each 
couple. The inclusion criteria were: cryop re-
served embryos after conventional in vitro fer-
tilization (IVF) or intracytoplasmic sperm in-
jection (ICSI)‚ maternal age of 20-40 years (on 
the day of embryo freezing)‚ regular menstrual 
cycle of 25-35 days, and body mass index of 
20-27 kg/m2. Exclusion criteria were: the use 
of testicular sperm for ICSI (ejaculated sperm 
only)‚ basal follicle stimulating hormone (FSH) 
levels ≥12 IU/l, stage III-IV endometriosis, and 
polycystic ovarian syndrome (PCOS).
Randomization
Patients were randomized to either group in 
a ratio of 1:1 by means of computer-generated 
random numbers on the day of participation. 
Group selection and randomization were per-
formed by a nurse not involved in the study, by 
using opaque sealed envelopes. Both the pa-
tients and the clinicians were aware of the al-
located arm.
Treatment protocol
Of the initial 109 women invited to partici-
pate, 102 were included in the study. All wom-
en had previously undergone IVF or ICSI with 
embryo cryopreservation. They were randomly 
allocated to either the progesterone (n=51) or 
the no-progesterone (n=51) groups. In the pro-
gesterone group, we excluded four women. One 
patient had an endometrial polyp and three pa-
tients had thin endometria. Similarly, three pa-
tients were excluded from the no-progesterone 
group because of endometrial polyps (2) and 
one patient who did not return to the study. 
Thus, in this study, 102 women each underwent 
an embryo transfer in a natural cycle. The final 
analysis was performed on 51 patients in each 
group. On the second or third days of the men-
strual cycle, all patients underwent transvagi-
nal ultrasounds and serum hormone analysis 
for FSH. Then, a vaginal ultrasonographic ex-
amination was performed on cycle days 10 and 
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repeated as necessary. Final oocyte maturation 
was achieved by intramuscular (IM) adminis-
tration of 10000 IU of hCG (Pregnyl, Daropa-
khsh, Iran) when an endometrial thickness of 8 
mm or more and a follicle of 18 mm were pre-
sent on the ultrasound. On the day of the hCG 
administration, we measured serum estradiol‚ 
progesterone and LH levels.
The progesterone group received 100mg/day 
of progesterone (Aburaihan Pharmaceutical 
Co., Tehran, Iran) IM, that began 36 hours af-
ter the hCG administration and continued until 
ten weeks of gestation if pregnancy occurred. 
Control patients received no progesterone.  In 
both groups, cryopreserved embryo transfer 
was performed with a Cook catheter (Cook Ire-
land Ltd.) five days after hCG administration. 
Serum β-hCG level was measured 14 days after 
the transfer.
Embryo freezing-thawing
 Morphology of fresh cleavage-stage embryos 
was evaluated according to the number of blas-
tomeres and degree of fragmentation. Embryo 
selection for transfer or freezing was performed 
in the morning of the transfer day. Embryos 
were considered suitable for freezing if they 
had <30% fragmentation. Cryopreservation of 
all embryos was undertaken with vitrification 
by the cryotop method on day 3 of pre implanta-
tion development in both groups. After two-step 
loading with equilibration solution that con-
tained ethylene glycol and dimethyl sulfoxide 
and a vitrification solution that contained eth-
ylene glycol, dimethyl sulfoxide and sucrose, 
a narrow glass capillary was used to load the 
embryos onto the cryotop. After loading, the 
majority of the solution was removed to leave 
only a thin layer that covered the embryos, after 
which the sample was quickly immersed into 
liquid nitrogen. Subsequently, the plastic cap 
was pulled over the film part of the cryotop and 
the sample stored in liquid nitrogen. At warm-
ing, the protective cap was removed from the 
cryotop while it was still submerged in liquid 
nitrogen and the cryotop was immersed direct-
ly into a 37˚C medium that contained sucrose. 
Next, the embryos were sequentially incubated 
in diluent solution before further in vitro culture 
for transfer. Each embryo was carefully evalu-
ated immediately after thawing for the number 
of surviving blastomeres, followed by a second 
evaluation the next morning. Embryos were ac-
cepted for transfer if they retained ≥50% of in-
tact blastomeres after thawing. 
 
Outcome measures
The main outcome measures concerned clini-
cal pregnancy and implantation rates. Chemi-
cal pregnancy was defined as serum β-hCG>50 
IU/L at 14 days after the embryo transfer. Clini-
cal pregnancy was defined as the presence of 
a gestational sac with heart beat identified by 
ultrasound 4-5 weeks after the embryo transfer. 
Implantation rate was defined as the ratio of 
gestational sacs to the number of embryos trans-
ferred. Clinical abortion rate was determined as 
clinically recognized pregnancy losses before 
20 weeks of gestation.
Sample size calculation
We considered a confidence interval of 95%, 
power of 80%, and difference of 25% in the 
pregnancy rate between the two groups to 
choose a sample size of 102 patients. It was cal-
culated that 51 subjects in each group would be 
an adequate number to achieve an 80% power 
of detection of difference at a significant level 
of 0.05.
Statistical analysis
The SPSS 19 package program was used to 
perform all statistical analyses. The normality of 
distribution of variables was tested by the Kol-
mogorov-Smirnov test. Independent sample t test 
was used for continuous variables which were 
normally distributed and Mann-Whitney U test for 
data not normally distributed. Chi-square or Fisher 
exact tests were used for qualitative variables as 
appropriate. A p value <0.05 was considered sta-
tistically significant. The data are presented as the 
mean ± standard deviation unless otherwise indi-
cated.
Results
There were no significant differences noted 
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in the fertilization rate between study and control 
groups (55.4% vs. 64.3%; p=0.16). Of the 102 pa-
tients included in this study, 51 received proges-
terone and the other 51 did not. Table 1 describes 
the basic characteristics of the patients in the two 
groups. The demographic parameters were similar 
in both groups in terms of age, basal FSH levels‚ 
body mass index (BMI)‚ the number of previous 
cycles‚ etiology of infertility, and infertility dura-
tion. Table 2 compares the previous fresh cycle 
characteristics in the two groups.
The mean number of oocytes retrieved‚ mean 
number of mature oocytes and the number of em-
bryos obtained and vitrified did not differ between 
the groups. There were no significant differences 
noted in the fertilization rate (55.4% vs. 64.3%; 
p=0.16).  In addition, the previous stimulation pro-
tocols and fertilization procedures were similar in 
the two groups. Only ejaculated sperms had used 
for conventional IVF or intracytoplasmic sperm 
injection and percent of sperms with progressive 
motility and sperms with normal morphology‚ also 
sperm count were not different in those groups. 
There was no significant difference observed 
between the groups regarding the reasons for 
embryo freezing. Table 3 compares the cycle 
characteristics of the two groups. Endometrial 
thickness and estradiol‚ progesterone and LH 
levels on the day of hCG administration were 
similar between groups.
The cycle length until the day of hCG admin-
istration‚ number of embryos transferred, and the 
number of good-quality embryos did not differ 
in the two groups. Table 4 presents a comparison 
of the pregnancy outcomes of the study groups. 
Again, no statistically significant differences were 
observed in the clinical pregnancy rate between 
the groups (33.3% vs.27.5%, p=0.66). Although 
there was a trend toward an increased clinical 
pregnancy rate with luteal supplementation‚ the 
difference was not significant. There were no dif-
ferences between the implantation rates (16.6% vs. 
15.3%‚ p=0.93) or clinical abortion rates (11.8% 
vs.14.3%‚ p=0.83). The flowchart of the study is 
shown in figure 1.
Table 1: Characteristics of patients
P valueNo progesteroneProgesteroneCharacteristic
N=51N=51
0.7128.7 ± 4.629.0 ± 3.8Age (Years)
0.3524.3 ± 2.423.8 ± 2.8BMI (kg/m2)
0.716.7 ± 4.56.0 ± 3.8Duration of infertility (Years)
0.906.0 ± 2.05.8 ± 1.9Basal FSH (IU/L)
0.5117 (33.3)14 (27.5)Previous ART attempts n (%)
0.62Etiology of infertility n (%)
32 (62.7)35 (68.6)Male factor
6 (11.8)7 (13.8)Tubal factor
13 (25.5)9 (17.6)Unexplained
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Table 2: Patients’ previous fresh cycle characteristics
P valueNo progesteroneProgesteroneCharacteristic
N=51N=51
0.84Type of previous stimulation n (%)
 31(60.8)29 (56.9)Agonist protocol
 20 (39.2)22 (43.1)Antagonist protocol
Fertilization procedure  n (%)
19 (37.3)11 (21.6)IVF
32 (62.7)40 (78.4)ICSI
0.169.6 ± 3.410.0 ±  4.3No. of oocytes retrieved
0.227.6 ± 2.88.3 ± 3.4No. of mature oocytes
0.195.7 ± 2.26.2 ± 1.6No. of embryos obtained
0.074.0 ± 0.64.3 ± 1.0No. of embryos vitrified
0.1664.355.4Fertilization rate (%)
Sperm parameters
0.6211.9 ± 7.012.6 ± 7.7Count (mill/ml)
0.7214.5 ± 6.915.0 ± 5.8Progressive motility (%)
0.5114.2 ± 7.315.3 ± 9.8Normal morphology (%)
0.59Cause of embryo freezing n (%)
26 (45.1)30 (58.8)Surplus embryos 
21(41.2)19 (37.3)Risk of OHSS
4 (7.8)2 (3.9)Endometrial polyp
Table 3: Frozen-thawed embryo replacement cycle characteristics
P valueNo progesteroneProgesteroneCharacteristic
N=51N=51
0.648.9 ± 1.48.7 ± 1.3Endometrial thickness (mm)
0.11196.9 ± 85.3
median: 170
208.4 ± 60.2
median: 200
E2 on hCG day (pg/ml)
0.080.80 ± 0.070.77 ± 0.09Progesterone on hCG day (ng/ml)
0.394.6 ± 1.74.9 ± 1.9LH on hCG day (IU/L)
0.0713.7 ± 1.514.3 ± 1.8No. of days until hCG
0.071.9  ± 0.5
median: 2
1.7 ± 0.5
median: 2
No. of embryos transferred
0.5460.854.9Transfers with good quality embryos (%)    
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Table 4: Pregnancy outcomes
No progesteroneProgesterone
P valueN=51N=51Outcome variable
0.8316 (31.4)18 (35.3)Chemical pregnancy rate‚ n (%)
0.6614 (27.5)17 (33.3)Clinical pregnancy rate‚ n (%)
0.9315.316.6Implantation rate (%)
0.832 (14.3)2 (11.8)Clinical abortion rate‚ n (%)
Fig 1: Flowchart of study patients.
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Discussion
The granulosa cells of the developing follicle gen-
erate estradiol in response to gonadotropin stimula-
tion in natural cycles. The endometrium acquires 
receptivity to embryo implantation by responding 
to progesterone action on an appropriately primed 
endometrium. Estrogenic stimulation would result in 
endometrial proliferation and the induction of pro-
gesterone receptors. The endometrium undertakes 
profound conformational and biochemical changes, 
from proliferative to secretory, with a concomitant 
induction of endometrial receptivity and opening of 
the window of implantation in response to progester-
one (20). During the implantation window, the endo-
metrium which is unexpectedly unreceptive towards 
embryo implantation acquires a functional condition 
useful to blastocyst reception (21).
The transfer of frozen-thawed embryos has important 
implications for the management of women undergoing 
ovarian hyperstimulation for IVF (2). Frozen embryo 
transfer is reported to be successful during the natural 
cycle after spontaneous ovulation according to the lit-
erature (22). In a study by Morozov et al. a higher preg-
nancy rate was observed in recipients who underwent 
natural cryothaw cycles than in hormone replacement 
treatment cycles. In their study the level of estradiol was 
greater in the substitution cycles when compared with 
the natural cycle. Regarding those results, we have sup-
ported the theory that the window of uterine receptivity 
closes earlier at a higher endogenous estrogen level and 
limits the time for the transferred embryos to implant 
successfully (9). According to their results,hormone 
replacement treatment versus the natural cycle for cry-
othaw embryo transfer was associated with decreased 
pregnancy rates. In the current study, we have evalu-
ated the outcome of hCG-induced natural cryothawed 
embryo transfer cycles that were supported during the 
luteal phase with IM progesterone. We compared this 
with the outcome of hCG-induced natural cycles in the 
absence of luteal phase support.
Our hypothesis was that progesterone support has a 
beneficial effect on pregnancy rate after frozen embryo 
transfer in natural cycles, but the results did not support 
our hypothesis. In our study, hCG was used for final oo-
cyte maturation. It was suggested that hCG administered 
for the final oocyte maturation in stimulated IVF cycles 
would cause a luteal phase defect by suppressing LH 
production through a short-loop feedback mechanism 
(23) although the use of hCG did not down-regulate LH 
secretion in the luteal phase of regular and unstimulated 
cycles in women with normal ovulation (24).  Addition-
ally, in our study none of the patients developed pre-
mature luteinization. Premature LH surge is defined as 
an LH level of ≥10 IU/L and a progesterone level of 
≥1.0 ng/ml on the day of hCG administration (25). An 
elevated progesterone level advances the endometrium‚ 
therefore the replacement of day 3 embryos occur in an 
asynchronous endometrium with subsequent failure of 
establishing an embryo-endometrium cross-dialog, re-
sulting in  implantation failure (26). 
Bourgain et al. have reported that progesterone in-
duces a secretory transformation of the endometrium in 
the luteal phase (27) and by inducing this change af-
ter sufficient estrogen priming, progesterone improves 
endometrial receptivity (28). Progesterone not only 
supports endometrial development but also maintains 
embryo survival by shifting the immune system toward 
the production of non-inflammatory Th2 cytokines (29, 
30). In addition, by inducing nitric oxide synthesis in the 
deciduas‚ they intensify local vasodilatation and uterine 
repose (31). A study by Orvieto et al. has shown that, 
in artificial cryothawed embryo transfer cycles, a high- 
dose progesterone supplementation in the luteal phase 
resulted in a higher clinical pregnancy rate (32).
In contrast to our study, Bjuresten et al. have reported 
that progesterone supplementation improved the live 
birth rate after embryo transfer in natural cycles (15). In 
their study, women received vaginal progesterone at a 
dose of 400 mg twice a day from the day of the embryo 
transfer. They attributed the increase in live birth rate 
to the effects of vaginal progesterone. Vaginal proges-
terone results in adequate endometrial development, in 
spite of low serum progesterone levels.
Our study was in agreement with a study by Kyrou et 
al. that reported luteal phase support did not affect on-
going pregnancy rates in natural hCG-induced frozen-
thawed embryo transfer cycles (33). A possible reason 
for our finding was that the women in the present study 
had a normal ovulatory function; those with ovulatory 
dysfunction were excluded from the study. Luteal phase 
defect in stimulated IVF cycles is due to supra physi-
ological levels of steroids which directly inhibit the LH 
release via negative feedback actions at the hypothalam-
ic-pituitary axis level (34). However it seems that LPD 
is not a main etiologic factor for implantation failure in 
natural frozen thawed embryo transfer cycles.
Conclusion
There emerged no significant differences between 
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the two groups in our study with regards to the im-
plantation or clinical pregnancy rates‚ but there was 
a trend toward an increased clinical pregnancy rate 
with luteal supplementation. Thus, further studies are 
needed to confirm our findings.
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